Real-world treatment utilization patterns, discontinuation and healthcare resource utilization of first-line Bruton tyrosine kinase inhibitors among elderly patients ≥65 years in chronic lymphocytic leukemia

Expert Review of Hematology · Published 2026-02-10 · DOI 10.1080/17474086.2026.2628534

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1080/17474086.2026.2628534

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Related articles